[en] OBJECTIVES: To investigate the mechanisms of action underlying the anti-inflammatory action of aceclofenac in vivo, we studied in vitro the effect of aceclofenac and its main metabolite, 4'-hydroxyaceclofenac, in comparison with diclofenac, another metabolite, on cyclooxygenases activity as well as interleukin-1beta, -6 and -8, nitric oxide, and prostaglandin E2 production by human osteoarthritic and normal articular chondrocytes. METHODS: Enzymatically isolated human chondrocytes were cultured for 72 h in the absence or presence of interleukin-1beta (IL-1beta) or lipopolysacharride (LPS) and with or without increased amounts (1 to 30 microM) of aceclofenac or metabolites. The production of different cytokines was measured by Enzyme Amplified Sensitivity Immunoassays (EASIA). Prostaglandin E2 was quantified by a specific radioimmunoassay. Nitrite and nitrate concentrations in the culture supernatants were determined by spectrophotometric method based upon the Griess reaction. Cyclooxygenase-2, inducible NO synthase and IL-1beta gene expression were quantified by reverse transcription of mRNA followed by real time and quantitative polymerase chain reaction. Finally, cyclooxygenase inhibitory potency of the drugs was also tested in both a cell-free system using purified ovine cyclooxygenase-1 and -2 (COX-1 and COX-2) and at a cellular level using human whole blood assay. RESULTS: We have demonstrated that aceclofenac, 4'-hydroxyaceclofenac and diclofenac significantly decreased interleukin-6 production at concentrations ranged among 1 to 30 microM and fully blocked prostaglandin E2 synthesis by IL-1beta- or LPS-stimulated human chondrocytes. Aceclofenac and diclofenac had no effect on interleukin-8 production while 4'-hydroxyaceclofenac slightly decreased this parameter at the highest dose (30 microM). Aceclofenac was without effect on IL-1beta- or LPS-stimulated nitric oxide production. At 30 microM, 4'-hydroxyaceclofenac inhibited both IL-1beta or LPS-stimulated nitric oxide production while diclofenac inhibited only the LPS-stimulated production. Finally, at 30 microM, the three drugs significantly decreased IL-1beta mRNA. In the whole blood test, aceclofenac and 4'-hydroxyaceclofenac weakly inhibited COX-1 with IC50 values superior to 100 microM, but decreased by 50% COX-2 activity at the concentration of 0.77 and 36 microM, respectively. Diclofenac strongly inhibited both COX-1 and COX-2 with IC50 values of 0.6 and 0.04 microM, respectively. On the other hand, aceclofenac and diclofenac weakly inhibited purified ovine cyclooxygenases with IC50 values superior to 100 microM, whereas 4'-hydroxyaceclofenac was without effect. CONCLUSIONS: These results suggest that aceclofenac actions are multifactorial and that metabolites could contribute to its anti-inflammatory actions.
Disciplines :
Rheumatology
Author, co-author :
Henrotin, Yves ; Université de Liège - ULiège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartillage (U.R.O.C.) - Didactique des sciences de la santé - Pathologie générale et physiopathologie
de Leval, X.
Mathy, Marianne ; Université de Liège - ULiège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartillage (U.R.O.C.)
Mouithys-Mickalad, Ange ; Université de Liège - ULiège > Centre de l'oxygène : Recherche et développement (C.O.R.D.)
Deby, Ginette ; Université de Liège - ULiège > Centre de l'oxygène : Recherche et développement (C.O.R.D.)
Dogné, Jean-Michel ; Université de Liège - ULiège > Département de pharmacie > Département de pharmacie
Delarge, J.
Reginster, Jean-Yves ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Language :
English
Title :
In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators.
Publication date :
2001
Journal title :
Inflammation Research
ISSN :
1023-3830
eISSN :
1420-908X
Publisher :
Springer Science & Business Media B.V., Basel, Switzerland
Birell D.H., Roma J., Bowdler J.M. (1995) Evaluation of the efficacy and safety of aceclofenac in the treatment of osteoarthritis. Br J Clin Res 6:45-55.
Batlle-Gualda E., Figueroa M., Ivorra J., Raber A. (1996) Aceclofenac-indomethacin study group. The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: A multicenter controlled clinical trial. J Rheumatol 23:1200-1206.
Pasero G., Marcolongo R., Semi U., Parnham M.J., Ferrer F. (1995) A multicentre, double-blind comparative study of the efficacy and safety of aceclofenac and diclofenac in the treatment of rheumatoid arthritis. Cur Med Res Opinion 13:305-315.
Hunter J.A., Parnham M.J., Gras I., Balaguer X. (1996) Aceclofenac in rheumatoid arthritis: A useful and novel anti-inflammatory. Clin Rheumatol 15:329-334.
Ward D.E., Veys E.M., Bowdler J.M., Roma J. (1995) Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis. Clin Rheumatol 14:656-662.
Kornasoff D., Frerick H., Bowdler J., Montull E. (1997) Aceclofenac is a well-tolerated alternative to naproxen in the treatment of osteoarthritis. Clin Rheumatol 16:32-38.
Kornasoff D., Maisenbacher J., Bowdler J., Raber A. (1996) The efficacy and tolerability of aceclofenac compared to indomethacin in patients with rheumatoid arthritis. Rheumatol Int 15:225-230.
Perez Busquier M., Calero E., Rodriguez M., Castellon Arce P., Bermudez A., Linares L.F. (1997) Comparison of aceclofenac with piroxicam in the treatment of osteoarthritis. Clin Rheumatol 16:154-159.
Perez-Ruiz F., Alonso-Ruiz A., Ansoleaga J.J. (1996) Comparative study of the efficacy and safety of aceclofenac and tenoxicam in rheumatoid arthritis. Clin Rheumatol 15:473-477.
Torrejón V.A. (1988) Treatment of severe rheumatic pain with aceclofenac. Results of comparative study vs placebo. Acta Ther 14:275-280.
Yamazaki R., Kawai S., Matsumoto T., Matsuzaki T., Hashimoto S., Yokokura T. (1999) Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells. JPET 289:676-681.
Gonzalez E., De la Cruz C., De Nicolas R., Egido J., Herrero-Beaumont G. (1994) Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agents Actions 41:171-178.
Gonzalez-Alvaro I., Carmona L., Diaz-Gonzalez F., Gonzalez-Amaro R., Mollinedo F., Sanchez-Madrid F. (1996) Aceclofenac, a new nonsteroidal antinflammatory drug, decreases the expression and function of some adhesion molecules on human neutrophils. J Rheumatol 23:723-729.
Dingle J.T. (1999) Non-steroidal, anti-inflammatory drugs administration in the treatment of osteoarthritis., Osteoarthritis: clinical and experimental aspects. Ed by J-Y Reginster, J-P Pelletier, J Martel-Pelletier, Y Henrotin. Springer; 370-387.
Dingle J.T., Parker M. (1997) NSAID stimulation of human cartilage matrix synthesis. A study of the mechanism of action of aceclofenac. Clin Drug Invest 14:353-362.
Henrotin Y., Mouithys-Mickalad A., Mathy-Hartert M., Zheng S.X., Deby G., Reginster J.-Y. (2000) The antioxidant properties of nonsteroidal anti-inflammatory drugs. Osteoarthritis Cartilage , TH042; 8(SUPPL. B).
Yamazaki R., Kawai S., Mitzushima Y., Matsuzaki T., Hoshimoto S., Yokokura T. (2000) A major metabolite of aceclofenac, 4′-hydroxy aceclofenac, suppresses the production of interstitial pro-collagenase/pro-MMP-1 and pro-stromelysin-1/proMMP-3 by rheumatoid synovial cells. Inflamm Res 49:133-138.
Bort R., Ponsoda X., Carrasco E., Gomez-Lechon M.J., Castell J.V. (1996) Metabolism of aceclofenac in humans. Drug Metab Dispos 24:834-841.
Yamazaki R., Kawai S., Matsuzaki T., Kaneda N., Hashimoto S., Yokokura T. (1997) Aceclofenac blocks prostaglandin E2 production following its intracellular conversion into cyclooxygenase inhibitors. Eur J Pharmacol 329:181-187.
Akimoto H., Yamazaki R., Hashimoto S., Sato T., Ito A. (2000) 4′-hydroxy-aceclofenac suppresses the interleukin-1-induced production of promatrix metalloproteinases and release of sulfated-glycos-aminoglycans from rabbit articular chondrocytes. Eur J Pharmacol 401:429-436.
Henrotin Y.E., Zheng S.X., Labasse A.H., Deby G.P., Crielaard J.-M., Reginster J.-Y. (2000) Modulation of human chondrocytes metabolism by recombinant human interferon. Osteoarthritis Cartilage 8:474-482.
Creamer J. (1992) A comparison of the pharmacokinetics of single and repeated doses of aceclofenac in young and elderly volunteers. Br J Clin Res 3:99-107.
Serteyn D., Deby-Dupont G., Pincemail J., Mottard E., Philippart C., Lamy M. (1988) Equine postanaesthetic myositis. Thromboxanes, prostacyclin and prostaglandin E2 production. Vet Res Commun 12:219-226.
Labarca A., Paigen K. (1981) A simple, rapid and sensitive DNA assay procedure. Anal Biochem 102:344-352.
Green L., Wagner D., Glogowski J., Skipper P., Wishnok J., Tannenbaum S. (1982) Analysis of nitrate, nitrite, and (15N) nitrate in biological fluids. Anal Biochem 126:131-138.
De Leval X., Dogné J.M., Neven P., Labasse A., Delarge J., Reginster J.Y. (1999) Effects of nimesulide and indometacin on COX-1 and COX-2: A comparative study. J Pharm Belg 54:89-90.
Splawski J.B., McAnally L., Lipsky P. (1990) IL-2 dependence of the promotion of human B cell differenciation by IL-6 (BSF-2). J Immunol 144:562-569.
Gauldie J., Northemann W., Fey G. (1990) IL-6 functions as an exocrine hormone in inflammation. Hepatocytes undergoing acute phase response require exogenous IL-6. J Immunol 144:3804-3808.
Martel-Pelletier J., Di Battista J., Lajeunesse D. Biochemical factors in joint articular tissue degradation in osteoarthritis. Osteoarthritis: clinical and experimental aspects , Edited by JY Reginster, JP Pelletier, J Pelletier, Y Henrotin. Springer; 1999, 156-187.
Guerne P.A., Zuraw B.L., Vaughan J.H., Carson D.A., Lotz M. (1989) Synovium as a source of interleukin-6 in vitro: Contribution to local and systemic manifestations of arthritis. J Clin Invest 83:585-692.
Nietfeld J.J., Wilbrink B., Helle M., Van Roy J.L., Den Otter W., Swaak A.J. (1990) Interleukin-l-induced interleukin-6 is required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. Arthritis Rheum 33:1695-1701.
Lidbury P., Vojnovic I., Warner T. (2000) COX-2/COX-1 selectivity of aceclofenac in comparison with celecoxib and rofecoxib in the human whole blood assay. Osteoarthritis Cartilage , TH053; 8(SUPPL. B):40.